Canine idiopathic dilated cardiomyopathy. Part II: Pathophysiology and therapy

Veterinary Journal

Volumn 162, Issue 3, 2001, Pages 182-195

  Borgarelli, M ^a   Tarducci, A ^a   Tidholm, A ^b   Haggstrom J ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b Albano Animal Hospital of Stockholm   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Angiotensin converting enzyme inhibitor; Beta adrenergic antagonist; Dilated cardiomyopathy; Dogs; Heart disease; Pathophysiology; Positive inotropes

Indexed keywords

AMRINONE; ATENOLOL; BENAZEPRIL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CARVEDILOL; DIGITALIS GLYCOSIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INOTROPIC AGENT; METOPROLOL; MILRINONE; NEUROHORMONE; PIMOBENDAN; PLACEBO;

CONGESTIVE HEART FAILURE; DISEASE COURSE; DOG DISEASE; DRUG INDICATION; HEART ATRIUM ENLARGEMENT; HEART DILATATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HORMONE RELEASE; HUMAN; INOTROPISM; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

CANIS FAMILIARIS;

EID: 0035191012     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1053/tvjl.2001.0616     Document Type: Review

References (152)

1. The characterization of ovine genes for atrial, brain, and C-type natriuretic peptides
2. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animal
3. Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilatated cardiomyopathy
4. Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment
5. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicentric, prospective, randomized, double blinded, placebo-controlled, long-term trial
6. 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes
7. Lymphocyte β-adrenoceptor downregulation in Great Danes with occult dilated cardiomyopathy (DCM) and with DCM and heart failure
8. Lymphocyte adrenoceptor downregulation DCM dogs
9. A symposium: Amrinone-introduction
10. Myocardial collagen matrix remodeling and congestive heart failure
11. Myocardial β-adrenergic receptor down regulation in heart failure
12. 1-adrenergic receptors in the nonfailing and failing human heart
13. Changes in myocardial and vascular receptors in heart failure
14. Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure (MOCHA)
15. 2-adrenoreceptors in human hearts: Properties, functions, and alteration in chronic heart failure
16. Congestive cardiomyopathy in Doberman Pinscher dogs
17. Thyroid-stimulating hormone tests in cardiomyopathic Doberman Pinschers: A retrospective study
18. CIBIS Investigators and Committees A randomized trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)
19. Hypothyroid diseases
20. C-type natriuretic peptide: The endothelial component of the natriuretic peptide system
21. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials
22. Atrial natriuretic peptide suppresses osmostimulated vasopressin release in young and elderly humans
23. Regulation of hypertrophy and atrophy in cultured adult heart cells
24. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: How do they relate to the resistance to atrial natriuretic peptides?
25. The renin-angiotensin-aldosterone system in chronic heart failure: Pathophysiology and implications for treatment
26. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease
27. Renal effects of atrial natriuretic factor
28. Atrial natriuretic peptide
29. Simon Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
30. Pathophysiology of heart failure
31. Committee on Evaluation and Management of Heart Failure Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
32. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
33. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of Cooperative Veterinary Enalapril study group
34. A role of the renin-angiotensin system in the evolution of cardiac memory
35. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation
36. The effect of digoxin on mortality and morbidity in patients with heart failure
37. Biochemical basis of thyroid hormone action in the heart
38. Epidemiological, clinical haematological and biochemical characteristics of canine hypothyroidism
39. Tissue angiotensin system in cardiovascular medicine. A paradigm shift?
40. Regulation of β-adrenoreceptor signaling in cardiac function and disease
41. The ten most commonly asked questions about Beta-blockers for the heart failure
42. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure
43. Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium
44. Digitalis and neurohormonal abnormalities in heart failure and implications for therapy
45. Sympathoneural profile of patients with idiopathic dilated cardiomyopathy (IDCM)
46. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure
47. Coronary vasodilation induced by intracoronary enalaprilat: An argument for the role of a local renin-angiotensin-system in patient with dilated cardiomyopathy
48. β-blockers in heart failure. Do they improve the quality as well as the quantity of life?
49. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
50. Effect of pimobendan on calcium sensitivity of skinned fibers isolated from human papillary muscles
51. +2 Activation and the inotropic effects of Pimobendan (Vetmedin): Comparison with milrinone
52. Chymase: Its pathophysiological roles and inhibitors
53. Plasma adenosine levels increase in patients with chronic heart failure
54. Is there still a role for digoxin in the treatment of cardiac disease?
55. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human hearts
56. Myocardial performance and extracellular ionized calcium in a severely failing human heart
57. Physiology and pathophysiology of atrial natriuretic peptides
58. BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure
59. Role of right and left atrial dimensions for release of atrial natriuretic peptide in left-sided valvular heart disease and idiopathic dilated cardiomyopathy
60. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease
61. Influence of dilated cardiomyopathy, myocarditis and cardiac transplantation on the relation between plasma atrial natriuretic factor and atrial pressures
62. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympatetic nervous activity
63. Turning off the signal: Desensitization of β-adrenergic receptor function
64. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure
65. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet
66. Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction
67. Acute and short term hemodynamic, echocardiographic and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicentric Prospective Veterinary evaluation of study group
68. Gamma-atrial natriuretic polypeptide-derived peptides in human plasma: Cosecretion of N-terminal gamma-ANP fragment and alpha-ANP
69. Positive inotropic and lusitropic effects of triiodothyronine in conscious dogs with pacing-induced cardiomyopathy
70. Treatment of advanced heart failure
71. C-type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa
72. A summary of phase IV clinical data on milrinone (Wincardin), a canine cardiotonic: Protocol H
73. Left ventricular function and failure
74. Efficacy of digoxin administration in dogs with idiopathic congestive cardiomyopathy
75. Echocardiographic and clinical effects of milrinone in dogs with myocardial failure
76. Management of heart failure
77. Clinical efficacy of Vetmedin in comparison to digoxin for the treatment of congestive heart failure in dogs
78. The contribution of sympathetic tone and the renin-angiotensin-aldosterone system in severe chronic heart failure: Response to specific inhibitors (prazosin and captopril)
79. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy
80. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial
81. 1-adrenergic receptor stimulation and blockade on contractility in humans
82. Atrial and brain natriuretic peptides: A dual natriuretic peptide system involved in circulatory homeostasis
83. Direct evidence from intrarenal recordings for increased central sympathetic outflow in patients with heart failure
84. Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation
85. Therapy of congestive heart failure in dogs with pimobendan
86. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
87. Angiotensin and aldosterone
88. The effect of the novel inodilator Pimobendan (Vetmedin) on heart failure status in Cocker Spaniels and Dobermans with idiopathic dilated cardiomyopathy
89. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
90. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro
91. Renin-angiotensin system: Genes to bedside
92. Adrenergic effects on the biology of the adult mammalian cardiocyte
93. Unified concept of the mechanism of action of digitalis: Influence of ventricular function and cardiac disease on hemodynamic response to fundamental contractile effect
94. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy
95. 1-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure
96. Neuroendocrine changes in chronic cardiac failure
97. Does angiotensin converting enzyme inhibitor therapy delay the onset of congestive heart failure or sudden death in Doberman Pinchers with occult dilated cardiomyopathy?
98. Up-regulated expression of angiotensin II type 1 receptor gene in human pathologic hearts
99. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure
100. Role of neurohormonal mechanisms in determing survival in patients with severe chronic heart failure
101. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study
102. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
103. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure
104. Effect of oral milrinone on mortality in severe chronic heart failure
105. An echocardiographic and electrocardiographic study of cardiovascular function in hypothyroid dogs
106. Is it possible to diagnose canine hypothyroidism?
107. Breed differences in the plasma renin activity and plasma aldosterone concentration of dogs
108. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency
109. Effects of pimobendan (UD-CG 115) on the contractile function of the normal and "postischemic" canine myocardium
110. Down regulation of lymphocyte adrenoreceptor subtypes in dogs affected by dilated cardiomyopathy
111. 1 and β-adrenoceptor concentrations in normal and affected Great Danes
112. Inodilator therapy for heart failure. Early, late, or not at all?
113. Tracer norepinephrine kinetics in coronary circulation of patient with heart failure secondary to chronic pressure and volume overload
114. Adrenergic control of myocardial contractility in consious dogs
115. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilatation in dogs with reduced ejection fraction
116. Atrial natriuretic polypeptide (ANP) in human ventricle. Increased gene expression of ANP in dilated cardiomyopathy
117. Upregulation of thyroid hormone receptor mRNA beta-1 and beta-2 subtypes in the myocardium of dogs with naturally occurring dilated cardiomyopathy or chronic valvular disease
118. Norepinephrine-stimulated hypertrophy of coltured rat myocardial cells in a alpha adrenergic response
119. Myocardial disease
120. Biochemical detection of left ventricular dysfunction in dogs
121. Primary myocardial disease in the dog
122. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?
123. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions
124. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
125. Ten years of natriuretic peptide research: A new dawn for their diagnostic and therapeutic use?
126. 1 expression in rat ventricular myocytes
127. Cardiac myocyte necrosis induced by angiotensin II
128. Lymphocyte beta adrenoceptor in dogs with dilated cardiomyopathy
129. Regulation of natriuretic peptide secretion by the heart
130. Plasma norepinephrine in congestive heart failure
131. Camine idiopathic dilated cardiomyopathy. Aetiology, clinical characteristics, epidemiology and pathology
132. Effects of naturally occuring symptomatic and asymptomatic dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide and thyroid hormone concentrations in dogs
133. Clinical safety of intravenous amrinone
134. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation
135. Effects of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: Therapeutic implications
136. Neurohormonal modulation in cardiovascular disease
137. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial
138. Hemodynamic profile of the cardiotonic agent pimobendan
139. Loss of high affinity cardiac β receptors in dogs with heart failure
140. Endogenous cathecolamine levels in chronic heart failure
141. Atrial natriuretic peptide concentration in congestive heart failure, chronic renal failure and hyperadrenocorticism
142. Long term β-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
143. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
144. Na,K-ATPase in isolated nephron segments in rats with experimental heart failure
145. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease
146. Pathophysiologic concentrations of human brain natriuretic peptide have functionally important biological actions in vivo
147. Natriuretic peptide system in human heart failure
148. Effects of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure
149. The cardiomyopathies and myocardites
150. A sustained increased in β-adrenoreceptors during long term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy
151. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy
152. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure